Community-Acquired Pneumonia Treatment
Outpatient Management – Previously Healthy Adults
Amoxicillin 1 g orally three times daily for 5–7 days is the preferred first-line therapy for previously healthy adults without comorbidities, providing superior pneumococcal coverage against 90–95% of Streptococcus pneumoniae isolates, including many penicillin-resistant strains 1.
- Doxycycline 100 mg orally twice daily for 5–7 days serves as an acceptable alternative when amoxicillin is contraindicated, offering coverage of both typical and atypical pathogens 1.
- Macrolide monotherapy (azithromycin 500 mg day 1, then 250 mg daily; or clarithromycin 500 mg twice daily) should only be used in areas where documented pneumococcal macrolide resistance is <25%; in most U.S. regions resistance is 20–30%, making macrolides unsafe as first-line therapy 1.
Outpatient Management – Adults with Comorbidities or Recent Antibiotic Use
For patients with chronic heart, lung, liver, or renal disease, diabetes, malignancy, or antibiotic use within 90 days, combination therapy is required 1.
- Option 1 – Combination therapy: Amoxicillin-clavulanate 875/125 mg orally twice daily plus azithromycin (500 mg day 1, then 250 mg daily) or doxycycline 100 mg twice daily provides comprehensive coverage of typical bacteria and atypical pathogens 1.
- Option 2 – Respiratory fluoroquinolone monotherapy: Levofloxacin 750 mg orally once daily or moxifloxacin 400 mg orally once daily for 5–7 days is reserved for patients with β-lactam allergy or contraindications to macrolides, acknowledging FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection) 1.
Hospitalized Patients (Non-ICU)
Two equally effective regimens exist with strong recommendations and high-quality evidence 1:
- β-lactam plus macrolide combination: Ceftriaxone 1–2 g IV once daily plus azithromycin 500 mg IV or orally daily provides coverage for typical pathogens (S. pneumoniae, Haemophilus influenzae, Moraxella catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella) 1.
- Respiratory fluoroquinolone monotherapy: Levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily is equally effective and associated with fewer clinical failures in systematic reviews 1.
- For penicillin-allergic patients, respiratory fluoroquinolone is the preferred alternative 1.
Critical Timing
Administer the first antibiotic dose in the emergency department immediately upon diagnosis; delays beyond 8 hours increase 30-day mortality by 20–30% in hospitalized patients 1.
Diagnostic Testing
Obtain blood cultures and sputum Gram stain/culture before initiating antibiotics in all hospitalized patients to enable pathogen-directed therapy and safe de-escalation 1.
Severe CAP Requiring ICU Admission
Combination therapy is mandatory for all ICU patients; β-lactam monotherapy is linked to higher mortality in critically ill individuals with bacteremic pneumococcal pneumonia 1.
- Preferred ICU regimen: Ceftriaxone 2 g IV once daily (or cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours) plus azithromycin 500 mg IV daily or a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) 1.
- For penicillin-allergic ICU patients, use aztreonam 2 g IV every 8 hours plus a respiratory fluoroquinolone 1.
Special Pathogen Coverage (Only When Risk Factors Present)
Pseudomonas aeruginosa
Add antipseudomonal coverage only when specific risk factors are present: structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization with IV antibiotics within 90 days, or prior respiratory isolation of P. aeruginosa 1.
- Antipseudomonal regimen: Piperacillin-tazobactam 4.5 g IV every 6 hours or cefepime 2 g IV every 8 hours plus ciprofloxacin 400 mg IV every 8 hours or levofloxacin 750 mg IV daily plus an aminoglycoside (gentamicin or tobramycin 5–7 mg/kg IV daily) for dual coverage 1.
Methicillin-Resistant Staphylococcus aureus (MRSA)
Add MRSA coverage only when risk factors are present: prior MRSA infection/colonization, recent hospitalization with IV antibiotics, post-influenza pneumonia, or cavitary infiltrates on imaging 1.
- MRSA regimen: Vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) or linezolid 600 mg IV every 12 hours, added to the base CAP regimen 1.
Duration of Therapy
Treat for a minimum of 5 days and continue until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability 1.
- Typical duration for uncomplicated CAP is 5–7 days 1.
- Extended courses of 14–21 days are required only for infections caused by Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli 1.
Transition from IV to Oral Therapy
Switch from IV to oral antibiotics when all clinical stability criteria are met: temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24 breaths/min, systolic blood pressure ≥90 mmHg, oxygen saturation ≥90% on room air, ability to maintain oral intake, and normal mental status—typically by hospital day 2–3 1.
- Oral step-down options include amoxicillin 1 g three times daily plus azithromycin 500 mg daily (or azithromycin alone after 2–3 days of IV therapy) 1.
Critical Pitfalls to Avoid
- Never use macrolide monotherapy in hospitalized patients; it fails to cover typical pathogens like S. pneumoniae and leads to treatment failure 1.
- Never use macrolide monotherapy in outpatients when local pneumococcal macrolide resistance exceeds 25%; this increases risk of breakthrough bacteremia 1.
- Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA warnings about serious adverse events and resistance concerns 1.
- Do not add broad-spectrum antipseudomonal or MRSA agents routinely; restrict to patients with documented risk factors to prevent resistance and adverse effects 1.
- Do not extend therapy beyond 7–8 days in responding patients without specific indications; longer courses increase antimicrobial resistance risk without improving outcomes 1.
Follow-Up and Monitoring
- Outpatient review at 48 hours (or sooner if symptoms worsen) to assess response, oral intake, and adherence 1.
- Routine follow-up at 6 weeks for all patients; chest radiograph only for those with persistent symptoms, abnormal physical findings, or high risk for underlying malignancy (smokers >50 years) 1.
- For hospitalized patients, monitor temperature, respiratory rate, pulse, blood pressure, and oxygen saturation at least twice daily to detect early deterioration 1.
- If no clinical improvement by day 2–3, obtain repeat chest radiograph, inflammatory markers (CRP, white blood cell count), and additional microbiologic specimens to evaluate for complications 1.